肺疾患治療薬市場：薬剤クラス別、適応症別、薬剤タイプ別、流通チャネル別、エンドユーザー別-2024～2030年の世界予測

肺疾患治療薬市場規模は2023年に793億5,000万米ドルと推計され、2024年には861億4,000万米ドルに達し、CAGR 8.03％で2030年には1,362億7,000万米ドルに達すると予測されます。

肺疾患治療薬市場には、呼吸器疾患の予防、診断、治療のために特別に設計された幅広い治療ソリューションが含まれます。肺疾患治療薬は主に、肺炎、結核、喘息、慢性閉塞性肺疾患（COPD）、嚢胞性線維症、アレルギー性鼻炎、その他の肺疾患など、様々な呼吸器疾患の治療に使用されます。肺疾患の有病率の上昇と疾患治療を促進する政府の取り組みにより、肺疾患治療薬のニーズが高まっています。肺疾患治療薬に対する償還政策の改善や政府の好意的な承認も市場成長に寄与しています。しかし、製品リコール事件が肺疾患治療薬の採用を制限する可能性があります。不適切なドラッグデリバリーや薬剤耐性の発達に伴う制限も、肺疾患治療薬の採用に課題をもたらすと予想されます。さらに、肺疾患治療のための新しい生物製剤や標的薬の開発、吸入ドラッグデリバリー療法の進歩は、市場に潜在的な成長機会をもたらすと期待されています。

薬剤クラス別：配合剤やモノクローナル抗体の開発が進み、肺疾患の個別化治療が可能に

抗コリン薬は、気道のインパルス伝達を担う神経伝達物質であるアセチルコリンの作用を阻害する薬剤クラス別です。これらの薬剤は気管支収縮と気道分泌物を減少させる働きがあり、慢性閉塞性肺疾患（COPD）や喘息の治療に有用です。抗ロイコトリエン薬は、気道収縮や粘液産生につながる免疫反応に関与する化学物質であるロイコトリエンの作用を阻害することで、呼吸器系の炎症と闘う薬です。主に喘息の治療に用いられ、特に吸入コルチコステロイドやβ2アゴニストなどの従来の治療薬に反応しない患者に使用されます。抗ヒスタミン薬は、アレルギー反応の際に放出される化学伝達物質であるヒスタミンを阻害することによって作用し、くしゃみ、かゆみ、鼻づまりなどのアレルギー症状を軽減します。抗ヒスタミン薬は、アレルギーに伴う喘息や慢性鼻炎の治療に有益であるが、主に肺疾患を対象としています。β2作動薬は、気管支平滑筋細胞上のβ2アドレナリン受容体を刺激し、喘息やCOPDの症状管理に不可欠な弛緩と気管支拡張を引き起こす肺疾患治療薬です。配合剤は、2種類以上の異なるクラスの薬剤を配合することで、副作用を最小限に抑えながら効果を高める。単剤治療で十分な症状コントロールが得られない場合に処方されることが多いです。モノクローナル抗体は、重症喘息などの炎症や免疫介在性気道疾患に関与する特定の細胞経路を標的とするように設計された生物学的薬剤です。コルチコステロイドは、経口および吸入の両方で、喘息やCOPDなどのさまざまな肺疾患の治療に使用される強力な抗炎症薬です。

適応COPDおよび嚢胞性線維症の治療・管理に有効な薬剤・薬物の必要性

アレルギー性鼻炎は、花粉、ダニ、動物のふけなどのアレルゲンにさらされることによって鼻腔に影響を及ぼす炎症性疾患です。この症状を管理するために最も一般的に使用される薬剤には、抗ヒスタミン薬、ロイコトリエン受容体拮抗薬、経鼻コルチコステロイドなどがあります。気管支喘息は、気道閉塞と気管支攣縮を示す慢性炎症性呼吸器疾患です。重症度や個々の患者のニーズに応じて、喘息管理には短時間作用型β作動薬（SABA）、長時間作用型β作動薬（LABA）、吸入コルチコステロイド（ICS）、または生物学的製剤が用いられます。慢性閉塞性肺疾患（COPD）は、慢性気管支炎と肺気腫を伴う肺疾患で、気流閉塞をもたらします。遺伝性疾患である嚢胞性線維症は、肺に濃い粘液を蓄積させ、慢性感染症や呼吸不全を引き起こします。主な治療法は、欠損した嚢胞性線維症膜貫通伝導調節因子（CFTR）タンパク質を調節薬で標的とし、気管支拡張薬、抗生物質、粘液溶解薬を用いて症状を管理することです。肺動脈性肺高血圧症（PAH）は、肺に血液を供給する動脈の血圧が高くなるまれな重篤な疾患です。PAHの治療に使用される主な薬剤クラス別には、エンドセリン受容体拮抗薬（ERA）、プロスタサイクリンアナログまたはアゴニスト、可溶性グアニル酸シクラーゼ刺激薬（sGCS）、ホスホジエステラーゼ5型阻害薬（PDE-5i）などがあります。

薬剤の種類肺疾患管理における費用対効果の高いジェネリック医薬品への嗜好の高まり

処方薬は、患者に調剤される前に医療従事者の処方箋が必要な医薬品です。これらの医薬品は、食品医薬品局（FDA）や欧州医薬品庁（EMA）などの政府機関から承認される前に、安全性と有効性を確保するための厳格な試験と規制プロセスを経ています。処方薬肺疾患治療薬は、呼吸器疾患の根本原因に対処するためにデザインされた、高度な作用機序を持つ標的療法を提供します。ジェネリック医薬品は、剤形、強さ、投与経路、品質、性能特性、使用目的において先発医薬品と生物学的に同等です。これらの医薬品は、先発医薬品の特許が切れた後に市場に投入され、通常、先発医薬品よりも低価格で販売されます。費用対効果は、長期的な治療が必要なヘルスケア・プロバイダーや経済的に余裕のない患者の間でジェネリック医薬品が好まれる主な要因となっています。

流通チャネル：患者や医療従事者への製品浸透のためのオンライン流通戦略の改善

病院薬局は肺疾患治療薬にとって不可欠な流通チャネルであり、その主な理由は医療施設内に戦略的に立地しているからです。そのため、医療従事者は慢性および急性の呼吸器疾患患者の救命薬にすぐにアクセスすることができます。オンライン薬局は、肺疾患治療薬を購入するための便利で費用対効果の高いプラットフォームとして登場しました。オンライン薬局は、玄関先までの配達、プライバシー、割引、薬局の店舗に行かなくても薬が手に入りやすいなどの利点があります。小売薬局は、広く存在し、患者が簡単にアクセスできることから、肺疾患治療薬の重要な流通チャネルを構成しています。

エンドユーザー：病院での急性症例や重症呼吸器疾患に対応する、即効性のある多様な薬剤の入手可能性

在宅医療分野では、喘息、結核、慢性閉塞性肺疾患（COPD）などの慢性呼吸器疾患患者は、定期的な投薬と管理が必要です。病院は、急性増悪や呼吸器疾患の重症例治療の重要なセンターとして機能しています。専門クリニックは、嚢胞性線維症、間質性肺疾患、肺動脈性肺高血圧症（PAH）など、特定の呼吸器疾患の患者に対応しています。

地域別洞察

南北アメリカ地域は、この地域の大手市場プレーヤーの存在により、肺疾患治療薬の製造インフラが高度に発達しています。米国、カナダ、ブラジルなどの主要国では、慢性閉塞性肺疾患、結核、喘息などの呼吸器疾患が小児および成人の間で流行しており、肺疾患治療薬のニーズが高まっています。ドイツ、フランス、イタリア、スペインなどのEMEA諸国も、高齢化人口の増加により呼吸器疾患の有病率が高く、同地域の市場成長に寄与しています。サウジアラビアやアラブ首長国連邦などの中東諸国は、この公衆衛生上の懸念に対処するため、医療インフラの改善に多額の投資を行っています。アジア地域は、中国、インド、日本などの主要国における政府投資の増加により、市場成長が見られます。同地域の市場関係者は、肺疾患用の手ごろな価格のジェネリック医薬品の製造と、国内での新薬開拓への投資に注力しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは肺疾患治療薬市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、肺疾患治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.肺疾患治療薬市場の市場規模および予測は？

2.肺疾患治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.肺疾患治療薬市場の技術動向と規制枠組みは？

4.肺疾患治療薬市場における主要ベンダーの市場シェアは？

5.肺疾患治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 肺疾患の蔓延と疾患治療および薬剤アクセスを促進する取り組み
    • 肺疾患治療薬の償還の改善と政府の承認の好意
  • 抑制要因
    • 肺疾患の治療に使用される薬剤の回収増加
  • 機会
    • 肺疾患治療のための新規生物学的製剤および標的薬の開発
    • 吸入ドラッグデリバリー療法と技術の進歩
  • 課題
    • 不適切なドラッグデリバリーと薬剤耐性の発現に関連する制限
• 市場セグメンテーション分析
  • 薬物クラス：肺疾患の個別化治療を提供するための複合薬とモノクローナル抗体の製剤の進歩
  • 適応症：COPDおよび嚢胞性線維症の治療と管理に効果的な薬剤の必要性
  • 薬剤の種類：肺疾患の管理において、費用対効果の高いジェネリック医薬品が好まれる傾向
  • 流通チャネル：患者とヘルスケア提供者の間での製品浸透を高めるためのオンライン流通戦略の改善
  • エンドユーザー：病院における急性症例や重篤な呼吸器疾患に対処するための、即効性のある多様な薬剤の提供
• 市場動向分析
  • 呼吸器疾患の罹患率の上昇と、疾患管理のための革新的な肺疾患治療薬を開発している大手市場プレーヤーの存在により、南北アメリカでは大幅な成長が見込まれます。
  • アジア太平洋における革新的な肺疾患治療薬の共同生産のための確立されたスペースは、医薬品の商業化に対する政府の財政支援によって大幅に支えられています。
  • ヘルスケアインフラの改善と政府の支援により、EMEAにおける肺疾患治療薬の要件を満たすための研究開発が重視される
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 肺疾患治療薬市場薬剤クラス別

• 抗コリン剤
• 抗ロイコトリエン
• 抗ヒスタミン薬
• ベータ2作動薬
• 併用薬
• モノクローナル抗体
• 経口および吸入コルチコステロイド

第7章 肺疾患治療薬市場適応症別

• アレルギー性鼻炎
• 喘息
• 慢性閉塞性肺疾患
• 嚢胞性線維症
• 肺動脈高血圧

第8章 肺疾患治療薬市場薬の種類別

• ジェネリック医薬品
• 処方薬

第9章 肺疾患治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第10章 肺疾患治療薬市場：エンドユーザー別

• ホームケア
• 病院
• 専門クリニック

第11章 南北アメリカの肺疾患治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の肺疾患治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの肺疾患治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • ブリッジ・バイオセラピューティクス、特発性肺線維症におけるBBT-877第2a相試験について独立データモニタリング委員会から肯定的な勧告を受けたと発表
  • ブリストルマイヤーズスクイブ、進行性肺線維症に対する治験中のLPA1拮抗薬が米国FDAの画期的治療薬に指定されたと発表
  • 喘息に特化した資金調達が加速する中、アイオロス・バイオが2億4,500万米ドルで設立
  • アヴァリン、IPF吸入薬開発のため1億7,500万米ドルの資金を調達
  • ルピンはマーク・キューバンおよびCOPD財団と提携し、米国におけるCOPD治療薬へのアクセスを拡大
  • アポロ・セラピューティクス、ユニ・調査に基づく医薬品開発のため2億2,650万米ドルを調達
  • ビアトリスは、キンデバと提携し、喘息および慢性閉塞性肺疾患患者向けのシムビコートのFDA承認ジェネリック版であるブレイナ（ブデソニドおよびフォルモテロールフマル酸塩二水和物）吸入エアロゾルの発売を発表
  • 米国FDA、高齢者のRSウイルス（RSV）予防のためのファイザー社製ワクチン「ABRYSVO」を承認
  • TFFとNIEHSが呼吸器疾患用の粉末製剤の開発で提携
  • 米国FDA、高齢者向けRSウイルス（RSV）ワクチン「アレキシー」をGSK社が承認
  • アストラゼネカ、新しい喘息治療薬「エアスープラ」を発売
  • C4XDとアストラゼネカ、呼吸器疾患治療薬の開発で4億200万米ドルの契約を締結

第15章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. PULMONARY DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. PULMONARY DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. PULMONARY DRUGS MARKET DYNAMICS
• FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 20. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 26. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PULMONARY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL & INHALED CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL & INHALED CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 58. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 59. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 60. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 61. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 62. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 63. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 64. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 69. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 70. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 71. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 72. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 73. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 74. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 75. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 76. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 77. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 78. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 79. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 80. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 81. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 82. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 83. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 84. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 85. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 86. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 87. BRAZIL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 88. BRAZIL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 89. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 90. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 91. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 92. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 93. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 94. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 95. CANADA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 96. CANADA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 97. CANADA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 98. CANADA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 99. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 100. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 101. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 102. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 103. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 104. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 105. MEXICO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 106. MEXICO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 107. MEXICO PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 108. MEXICO PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 109. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 110. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 111. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 112. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 113. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 114. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 115. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 116. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 117. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 118. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 119. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 120. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 122. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 123. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 124. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 125. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 126. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 127. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 128. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 129. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 130. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 131. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 132. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 133. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 134. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 135. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 136. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 137. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 138. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 139. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 140. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 141. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 142. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 143. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 144. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 145. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 146. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 147. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 148. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 149. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 150. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 151. CHINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 152. CHINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 153. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 154. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 155. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 156. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 157. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 158. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 159. INDIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 160. INDIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 161. INDIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 162. INDIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 163. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 164. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 165. INDONESIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 166. INDONESIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 167. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 168. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 169. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 170. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 171. INDONESIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 172. INDONESIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 173. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 174. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 175. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 176. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 177. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 178. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 179. JAPAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 180. JAPAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 181. JAPAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 182. JAPAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 183. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 184. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 185. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 186. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 187. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 188. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 189. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 190. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 191. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 192. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 193. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 194. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 195. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 196. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 197. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 198. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 199. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 200. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 201. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 202. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 203. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 204. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 205. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 206. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 207. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 208. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 209. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 210. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 211. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 212. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 213. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 214. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 215. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 216. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 217. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 218. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 219. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 220. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 221. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 222. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 223. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 224. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 225. TAIWAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 226. TAIWAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 227. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 228. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 229. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 230. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 231. TAIWAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 232. TAIWAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 233. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 234. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 235. THAILAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 236. THAILAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 237. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 238. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 239. THAILAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 240. THAILAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 241. THAILAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 242. THAILAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 243. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 244. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 245. VIETNAM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 246. VIETNAM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 247. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 248. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 249. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 250. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 251. VIETNAM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 252. VIETNAM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 263. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 264. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 265. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 266. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 267. DENMARK PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 268. DENMARK PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 269. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 270. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 271. DENMARK PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 272. DENMARK PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 273. DENMARK PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 274. DENMARK PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 275. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 276. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 277. EGYPT PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 278. EGYPT PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 279. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 280. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 281. EGYPT PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 282. EGYPT PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 283. EGYPT PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 284. EGYPT PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 285. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 286. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 287. FINLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 288. FINLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 289. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 290. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 291. FINLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 292. FINLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 293. FINLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 294. FINLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 295. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 296. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 297. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 298. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 299. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 300. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 301. FRANCE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 302. FRANCE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 303. FRANCE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 304. FRANCE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 305. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 306. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 307. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 308. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 309. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 310. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 311. GERMANY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 312. GERMANY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 313. GERMANY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 314. GERMANY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 315. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 316. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 317. ISRAEL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 318. ISRAEL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 319. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 320. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 321. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 322. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 323. ISRAEL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 324. ISRAEL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 325. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 326. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 327. ITALY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 328. ITALY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 329. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 330. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 331. ITALY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 332. ITALY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 333. ITALY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 334. ITALY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 335. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 336. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 337. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 338. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 339. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 340. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 341. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 342. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 343. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 344. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 345. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 346. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 347. NIGERIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 348. NIGERIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 349. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 350. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 351. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 352. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 353. NIGERIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 354. NIGERIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 355. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
• TABLE 356. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
• TABLE 357. NORWAY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 358. NORWAY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 359. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 360. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 361. NORWAY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)

TABLE

[198 Pages Report] The Pulmonary Drugs Market size was estimated at USD 79.35 billion in 2023 and expected to reach USD 86.14 billion in 2024, at a CAGR 8.03% to reach USD 136.27 billion by 2030.

The pulmonary drugs market encompasses a wide range of therapeutic solutions specifically designed for the prevention, diagnosis, and treatment of respiratory diseases. Pulmonary drugs are primarily used in treating various respiratory conditions such as pneumonia, tuberculosis, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, allergic rhinitis, and other pulmonary ailments. The rising prevalence of pulmonary diseases and government initiatives to promote disease treatment have increased the need for pulmonary drugs. The improvements in reimbursement policies and favorable government approvals for pulmonary drugs also contribute to market growth. However, incidents of product recalls may limit the adoption of pulmonary drugs. The limitations associated with improper drug delivery and the development of drug resistance are also expected to create challenges in the adoption of pulmonary drugs. Moreover, The development of new biologics & targeted drugs for pulmonary disease treatment and advancements in inhaled drug delivery therapies are expected to create potential growth opportunities in the market.

Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases

Anticholinergic agents are a class of drugs that block the action of acetylcholine, a neurotransmitter responsible for transmitting impulses in the airways. These medications help reduce bronchoconstriction and airway secretions, making them useful for treating chronic obstructive pulmonary disease (COPD) and asthma. Anti-leukotrienes are medications that combat inflammation in the respiratory system by blocking the effects of leukotrienes, which are chemicals involved in immune responses leading to airway constriction and mucus production. They are used primarily to treat asthma, especially in patients who do not respond well to traditional treatments such as inhaled corticosteroids or beta-2 agonists. Antihistamines work by inhibiting histamine, a chemical mediator released during allergic reactions, thereby reducing allergy symptoms such as sneezing, itching, and nasal congestion. Antihistamines can be beneficial in treating asthma and chronic rhinitis associated with allergies; however, it is primarily intended for pulmonary conditions. Beta-2 agonists are pulmonary drugs that stimulate beta-2 adrenergic receptors on bronchial smooth muscle cells, causing relaxation and bronchodilation, which is essential for managing asthma and COPD symptoms. Combination drugs contain two or more different classes of medications to enhance efficacy while minimizing side effects. They are often prescribed when single-agent therapies do not provide adequate symptom control. Monoclonal antibodies are biological drugs engineered to target specific cellular pathways involved in inflammatory and immune-mediated airway diseases, such as severe asthma. Corticosteroids, both oral and inhaled, are potent anti-inflammatory agents used to treat various pulmonary disorders such as asthma and COPD.

Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis

Allergic rhinitis is an inflammatory condition that impacts the nasal passages due to exposure to allergens, including pollen, dust mites, or animal dander. The most commonly used medications for managing this condition include antihistamines, leukotriene receptor antagonists, and intranasal corticosteroids. Asthma is a chronic inflammatory respiratory disease portraying airway obstruction and bronchospasm. Depending on the severity and individual patient needs, asthma management can involve short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), or biologics. Chronic obstructive pulmonary disease (COPD) is a lung disease involving chronic bronchitis and emphysema that results in airflow obstruction. Cystic fibrosis, a genetic disorder, causes the accumulation of thick mucus in the lungs, causing chronic infections and respiratory failure. The primary treatment approach involves targeting the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein with modulators and managing symptoms using bronchodilators, antibiotics, and mucolytics. Pulmonary arterial hypertension (PAH) is a rare, severe disorder leading to high blood pressure in the arteries supplying blood to the lungs. The main classes of drugs utilized to treat PAH include endothelin receptor antagonists (ERAs), prostacyclin analogs or agonists, soluble guanylate cyclase stimulators (sGCS), and phosphodiesterase type 5 inhibitors (PDE-5i).

Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management

Prescription drugs are medications that require a prescription from a licensed healthcare professional before they can be dispensed to patients. These medications undergo rigorous testing and regulatory processes to ensure safety and efficacy before being approved by governing agencies such as the Food & Drug Administration (FDA) or the European Medicines Agency (EMA). Prescription pulmonary drugs offer targeted therapies with advanced mechanisms of action designed to address the underlying causes of respiratory diseases. Generic drugs are bioequivalent to branded drugs in dosage form, strength, route of administration, quality, performance characteristics, and intended use. These drugs enter the market after the patent expiration of their branded counterparts and are typically priced lower than the original products. The cost-effectiveness is a primary factor driving the preference for generic drugs among healthcare providers and patients who require long-term treatments or have limited financial resources.

Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers

Hospital pharmacies are an essential distribution channel for pulmonary drugs, primarily due to their strategic location within healthcare facilities. This enables healthcare professionals to have immediate access to life-saving medications for patients with chronic and acute respiratory disorders. Online pharmacies have emerged as a convenient and cost-effective platform for purchasing pulmonary drugs. They offer advantages such as doorstep delivery, privacy, discounts, and ease of access to medications without needing a physical visit to a pharmacy store. Retail pharmacies constitute a significant distribution channel for pulmonary drugs, owing to their widespread presence and ease of access for patients.

End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals

In the homecare segment, patients with chronic respiratory diseases, including asthma, tuberculosis, and chronic obstructive pulmonary disease (COPD) require regular medication and management. Hospitals serve as critical centers for the treatment of acute exacerbations and severe cases of respiratory disorders. Specialty clinics cater to patients with specific respiratory conditions, including cystic fibrosis, interstitial lung diseases, and pulmonary arterial hypertension (PAH).

Regional Insights

The Americas region has a highly developed infrastructure for manufacturing of pulmonary drugs due to the presence of major market players in the area. In major countries such as the United States, Canada, and Brazil, respiratory diseases such as Chronic Obstructive Pulmonary Disease, Tuberculosis, and Asthma are prevalent among both children and adults, increasing the need for pulmonary drugs. EMEA countries, including Germany, France, Italy, Spain, and others, also have a high prevalence of respiratory disorders owing to the growing aging population, contributing to the market growth in the region. Middle-East countries such as Saudi Arabia and the UAE have invested heavily in health infrastructure improvements to address this public health concern. The Asian region is witnessing market growth due to increasing government investments in major countries such as China, India, and Japan. The market players in the region concentrate on producing affordable generics for pulmonary conditions and investing in the development of new drugs domestically.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pulmonary Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pulmonary Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pulmonary Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Chiesi Farmaceutici S.p.A, Cipla Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Grifols, S.A., Icosavax, Inc., Johnson & Johnson Services, Inc., Lung Therapeutics Inc., Lupin Pharmaceuticals, Inc., Mallinckrodt PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Sanofi S.A, Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, Verona Pharma PLC, Vertex Pharmaceuticals Incorporated, Viatris Inc., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Pulmonary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Drug Class
  • Anti-Cholinergic Agents
  • Anti-Leukotrienes
  • Antihistamines
  • Beta-2 Agonists
  • Combination Drugs
  • Monoclonal Antibodies
  • Oral & Inhaled Corticosteroids

• Indication
  • Allergic Rhinitis
  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Cystic Fibrosis
  • Pulmonary Arterial Hypertension

• Drug Type
  • Generic Drugs
  • Prescription Drugs

• Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

• End-User
  • Homecare
  • Hospitals
  • Specialty Clinics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pulmonary Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pulmonary Drugs Market?

3. What are the technology trends and regulatory frameworks in the Pulmonary Drugs Market?

4. What is the market share of the leading vendors in the Pulmonary Drugs Market?

5. Which modes and strategic moves are suitable for entering the Pulmonary Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of pulmonary diseases and initiatives to promote disease treatment and drug accessibility
    • 5.1.1.2. Improvements in reimbursements and favorable government approvals for pulmonary drugs
  • 5.1.2. Restraints
    • 5.1.2.1. Increasing recall of drugs used for pulmonary conditions
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of new biologics and targeted drugs for pulmonary disease treatment
    • 5.1.3.2. Advancements in inhaled drug delivery therapies and technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations associated with improper drug delivery and development of drug resistance
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases
  • 5.2.2. Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis
  • 5.2.3. Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management
  • 5.2.4. Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers
  • 5.2.5. End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals
• 5.3. Market Trend Analysis
  • 5.3.1. Significant growth in the Americas due to rising respiratory disease prevalence and the presence of major market players developing innovative pulmonary drugs for disease management.
  • 5.3.2. Well-established space for collaborative production of innovative pulmonary drugs in the Asia-Pacific substantially backed by the government's financial support for drug commercialization
  • 5.3.3. Improving healthcare infrastructure and government support emphasize research and development to meet the pulmonary drug requirement in EMEA
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis

6. Pulmonary Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Anti-Cholinergic Agents
• 6.3. Anti-Leukotrienes
• 6.4. Antihistamines
• 6.5. Beta-2 Agonists
• 6.6. Combination Drugs
• 6.7. Monoclonal Antibodies
• 6.8. Oral & Inhaled Corticosteroids

7. Pulmonary Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Allergic Rhinitis
• 7.3. Asthma
• 7.4. Chronic Obstructive Pulmonary Disease
• 7.5. Cystic Fibrosis
• 7.6. Pulmonary Arterial Hypertension

8. Pulmonary Drugs Market, by Drug Type

• 8.1. Introduction
• 8.2. Generic Drugs
• 8.3. Prescription Drugs

9. Pulmonary Drugs Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. Pulmonary Drugs Market, by End-User

• 10.1. Introduction
• 10.2. Homecare
• 10.3. Hospitals
• 10.4. Specialty Clinics

11. Americas Pulmonary Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Pulmonary Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Pulmonary Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
  • 14.3.2. Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
  • 14.3.3. Aiolos Bio Launches With USD 245 millions As Asthma-Focused Funding Accelerates
  • 14.3.4. Avalyn Raises USD 175 Million in Funding to Develop Inhaled IPF Drugs
  • 14.3.5. Lupin Partners With Mark Cuban and COPD Foundation to Expand Access to COPD Medication in the US
  • 14.3.6. Apollo Therapeutics Raises USD 226.5 million to Develop Medicines Based on Uni Research
  • 14.3.7. Viatris Announces Launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the FDA-Approved Generic Version of Symbicort for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
  • 14.3.8. U.S. FDA Approves ABRYSVO, Pfizer's Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
  • 14.3.9. TFF and NIEHS Partner to Develop Powder Formulations for Respiratory Diseases
  • 14.3.10. US FDA Approves GSK's Arexvy, a Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
  • 14.3.11. AstraZeneca Launches New Asthma Medication Called Airsupra
  • 14.3.12. C4XD and AstraZeneca Enter USD 402 million Deal to Develop Respiratory Disease Therapy

15. Competitive Portfolio

• 15.1. Key Company Profiles
• 15.2. Key Product Portfolio